BioCryst Pharmaceuticals(BCRX) - 2024 Q4 - Annual Results

Financial Performance - ORLADEYO® (berotralstat) net revenue for full year 2024 reached $437 million, a 34% year-over-year increase[8] - The company expects to approach quarterly earnings per share profitability in the second half of fiscal year 2025[4] Guidance and Forecasts - The company provided guidance for full year 2025 ORLADEYO net revenue and total revenue[4] - Full year 2025 operating expenses guidance was also provided[4] Corporate Events and Announcements - BioCryst will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025[4] - Preliminary unaudited results for Q4 and full year 2024 were announced on January 10, 2025[4]